Nonabsorbable disaccharides have been the mainstay of treatment for hepatic encephalopathy since introduced into clinical practice in 1966. Their beneficial effects reflect their ability to reduce the intestinal production/absorption of ammonia. A recent Cochrane review confirmed the efficacy and safety of nonabsorbable disaccharides for the treatment and prevention of hepatic encephalopathy in patients with cirrhosis. The findings were robust and support the use of nonabsorbable disaccharides as a first line treatment for hepatic encephalopathy, in this patient population, and for its prevention
In order to reduce ammonia production by urease-positive bacteria Solga recently hypothesised (S.F. ...
Mohamad Rasm Al Sibae, Brendan M McGuireDepartment of Medicine, Division of Gastroenterology and Hep...
Mirashini Swaminathan,1 Mark Alexander Ellul,2 Timothy JS Cross1 1Department of Gastroenterology, Ro...
Non-absorbable disaccharides (NADs) have been used to treat hepatic encephalopathy (HE) since 1966. ...
Context Guidelines for the treatment of hepatic encephalopathy suggest ammonia reduction as the main...
none8siHepatic encephalopathy (HE) is a serious complication of acute and chronic liver disease asso...
Clinical progress in the development of new diagnostic modalities and therapeutic strategies for the...
Altered gut microecology is considered a key pathogenetic factor in the development of both intestst...
Clinical progress in the development of new diagnostic modalities and therapeutic strategies for the...
Type-C hepatic encephalopathy (HE) is a severe complication of cirrhosis, which seriously affects qu...
Current recommendations for the treatment of hepatic encephalopathy are based, to a large extent, on...
Current recommendations for the treatment of hepatic encephalopathy are based, to a large extent, on...
Minimal hepatic encephalopathy has been shown to increase risk of involvement in road traffic accide...
Background: The mechanism of cerebral dysfunction in hepatic encephalopathy is unknown, althoughammo...
Hepatic encephalopathy (HE) is an extra hepatic complication of liver cirrhosis. The clinical manife...
In order to reduce ammonia production by urease-positive bacteria Solga recently hypothesised (S.F. ...
Mohamad Rasm Al Sibae, Brendan M McGuireDepartment of Medicine, Division of Gastroenterology and Hep...
Mirashini Swaminathan,1 Mark Alexander Ellul,2 Timothy JS Cross1 1Department of Gastroenterology, Ro...
Non-absorbable disaccharides (NADs) have been used to treat hepatic encephalopathy (HE) since 1966. ...
Context Guidelines for the treatment of hepatic encephalopathy suggest ammonia reduction as the main...
none8siHepatic encephalopathy (HE) is a serious complication of acute and chronic liver disease asso...
Clinical progress in the development of new diagnostic modalities and therapeutic strategies for the...
Altered gut microecology is considered a key pathogenetic factor in the development of both intestst...
Clinical progress in the development of new diagnostic modalities and therapeutic strategies for the...
Type-C hepatic encephalopathy (HE) is a severe complication of cirrhosis, which seriously affects qu...
Current recommendations for the treatment of hepatic encephalopathy are based, to a large extent, on...
Current recommendations for the treatment of hepatic encephalopathy are based, to a large extent, on...
Minimal hepatic encephalopathy has been shown to increase risk of involvement in road traffic accide...
Background: The mechanism of cerebral dysfunction in hepatic encephalopathy is unknown, althoughammo...
Hepatic encephalopathy (HE) is an extra hepatic complication of liver cirrhosis. The clinical manife...
In order to reduce ammonia production by urease-positive bacteria Solga recently hypothesised (S.F. ...
Mohamad Rasm Al Sibae, Brendan M McGuireDepartment of Medicine, Division of Gastroenterology and Hep...
Mirashini Swaminathan,1 Mark Alexander Ellul,2 Timothy JS Cross1 1Department of Gastroenterology, Ro...